Randomized trial shows canagliflozin reduces albuminuria and slows eGFR decline in type 2 diabetes, suggesting individual slope analysis effectively assesses early kidney protection.
per year, which was more pronounced in participants with faster eGFR decline. In summary, canagliflozin reduced albuminuria and the participant-specific natural course of eGFR decline in participants with type 2 diabetes and microalbuminuria. Thus, the CANPIONE study suggests that the within-individual change in eGFR slope may be a novel approach to determine the kidney protective potential of new therapies in early stages of CKD.
No takes yet. Share an insight, caveat, or question.
Miyamoto et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: